Acadia Pharmaceuticals | ACAD - Selling And Administration Expenses


Acadia Pharmaceuticals reported $160.79M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
ALKERMES USD 264.59M 77.4M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Corcept Therapeutics USD 128.04M 13.3M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Eisai JPY 119.54B 7.82B Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
J&J USD 6.03B 719M Mar/2026
Moderna USD 173M 135M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Prothena USD 7.65M 5.59M Dec/2025
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026